Olga Simo-Servat

Dr. Olga Simo-Servat


Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 May 2019 in Ophthalmic Research
Verified
Journal Article
Open access
PDF file
OSOlga Simo-Servat
Olga Simo-Servat
CHCristina Hernández
Cristina Hernández
Rafael SimóRafael Simó
Rafael Simó
Diabetic retinopathy (DR) is the most frequent complication of diabetes. The main risk factors are disease duration, a poor glycemic control, and the presence of hypertension. However, there is an important variation in risk which indicates that other factors, such as genetic heritability or glycemic variability, play an important role in accounting for the susceptibility to DR development. Another important concept is that DR is an independent predictor of both microvascular and macrovascular complications. Thus, the presence of DR should be taken into account when evaluating the cardiovascular risk of a diabetic subject. Moreover, the evaluation of retinal neurodegeneration could help to identify those diabetic subjects at risk of cognitive impairment, an emerging complication of the type 2 diabetic population. When evaluating a diabetic subject, the awareness of the presence of DR has also therapeutic implications. In this regard, a worsening of DR could occur after a rapid improvement of blood glucose. In summary, a critical review on the importance of the presence of DR in the general management of subjects with diabetes is provided.

1 May 2018 in Investigative Ophthalmology & Visual Science
Verified
Journal Article
Open access
PDF file
Jeffrey SundstromJeffrey Sundstrom
Jeffrey Sundstrom
CHCristina Hernández
Cristina Hernández
SWSarah R. Weber
Sarah R. Weber
YZYuanjun Zhao
Yuanjun Zhao
MDMitchell Dunklebarger
Mitchell Dunklebarger
Rafael SimóRafael Simó
Rafael Simó
Purpose: Current evidence suggests that retinal neurodegeneration is an early event in the pathogenesis of diabetic retinopathy. Our main goal was to examine whether, in the diabetic human retina, common proteins and pathways are shared with brain neurodegenerative diseases. Methods: A proteomic analysis was performed on three groups of postmortem retinas matched by age: nondiabetic control retinas (n = 5), diabetic retinas without glial activation (n = 5), and diabetic retinas with glial activation (n = 5). Retinal lysates from each group were pooled and run on an SDS-PAGE gel. Bands were analyzed sequentially by liquid chromatography-mass spectrometry (LC/MS) using an Orbitrap Mass Spectrometer. Results: A total of 2190 proteins were identified across all groups. To evaluate the association of the identified proteins with neurological signaling, significant signaling pathways belonging to the category “Neurotransmitters and Other Nervous System Signaling” were selected for analysis. Pathway analysis revealed that “Neuroprotective Role of THOP1 in Alzheimer's Disease” and “Unfolded Protein Response” pathways were uniquely enriched in control retinas. By contrast, “Dopamine Degradation” and “Parkinson's Signaling” were enriched only in diabetic retinas with glial activation. The “Neuregulin Signaling,” “Synaptic Long Term Potentiation,” and “Amyloid Processing” pathways were enriched in diabetic retinas with no glial activation. Conclusions: Diabetes-induced retinal neurodegeneration and brain neurodegenerative diseases, such as Alzheimer's and Parkinson's diseases, share common pathogenic pathways. These findings suggest that the study of neurodegeneration in the diabetic retina could be useful to further understand the neurodegenerative processes that occur in the brain of persons with diabetes.

1 January 2012 in Mediators of Inflammation
Verified
Journal Article
Open access
PDF file
OSOlga Simo-Servat
Olga Simo-Servat
CHCristina Hernández
Cristina Hernández
Rafael SimóRafael Simó
Rafael Simó
Diabetic retinopathy (DR) is the major cause of acquired blindness in working-age adults. Current treatments for DR (laser photocoagulation, intravitreal corticosteroids, intravitreal antivascular endothelial growth factor (VEGF) agents, and vitreo-retinal surgery) are applicable only at advanced stages of the disease and are associated with significant adverse effects. Therefore, new pharmacological treatments for the early stages of the disease are needed. Vitreous fluid obtained from diabetic patients undergoing vitreoretinal surgery is currently used to explore the events that are taking place in the retina for clinical research. However, several confounding factors such as vitreous haemorrhage and concentration of vitreous proteins should be considered in the analysis of the results. In this paper we will focus on the vitreous fluid as a tool for exploring the mediators of DR and in particular the molecules related to inflammatory pathways. In addition, their role in the pathogenesis of DR will be discussed. The usefulness of new technologies such as flow cytometry and proteomics in identifying new candidates involved in the inflammatory process that occurs in DR will be overviewed. Finally, a more personalized treatment based on vitreous fluid analysis aiming to reduce the burden associated with DR is suggested.

23 August 2021 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
Rafael SimóRafael Simó
Rafael Simó
OSOlga Simo-Servat
Olga Simo-Servat
PBPatricia Bogdanov
Patricia Bogdanov
CHCristina Hernandez
Cristina Hernandez
The concept of diabetic retinopathy as a microvascular disease has evolved and is now considered a more complex diabetic complication in which neurovascular unit impairment plays an essential role and, therefore, can be considered as a main therapeutic target in the early stages of the disease. However, neurodegeneration is not always the apparent primary event in the natural story of diabetic retinopathy, and a phenotyping characterization is recommendable to identify those patients in whom neuroprotective treatment might be of benefit. In recent years, a myriad of treatments based on neuroprotection have been tested in experimental models, but more interestingly, there are drugs with a dual activity (neuroprotective and vasculotropic). In this review, the recent evidence concerning the therapeutic approaches targeting neurovascular unit impairment will be presented, along with a critical review of the scientific gaps and problems which remain to be overcome before our knowledge can be transferred to clinical practice.

11 March 2019 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
JSJoel Sampedro
Joel Sampedro
PBPatricia Bogdanov
Patricia Bogdanov
HAHugo Ramos Abellan
Hugo Ramos Abellan
CSCristina Solà-Adell
Cristina Solà-Adell
MTMireia Turch
Mireia Turch
CHCristina Hernandez
Cristina Hernandez
The main goals of this work were to assess whether the topical administration of glucagon-like peptide-1 (GLP-1) could revert the impairment of the neurovascular unit induced by long-term diabetes (24 weeks) in diabetic mice and to look into the underlying mechanisms. For that reason, db/db mice were treated with eye drops of GLP-1 or vehicle for 3 weeks. Moreover, db/+ mice were used as control. Studies performed in vivo included electroretinogramand the assessment of vascular leakage by using Evans Blue. NF-κB, GFAP and Ki67 proteins were analyzed by immunofluorescence (IF). Additionally, caspase 9, AMPK, IKBα, NF-κB, AKT, GSK3, β-catenin, Bcl-xl, and VEGF were analyzed by WB. Finally, VEGF, IL-1β, IL-6, TNF-α, IL-18, and NLRP3 were studied by reverse transcription-polymerase chain reaction (RT-PCR) and immunofluorescence. We found that topical administration of GLP-1 reverted reactive gliosis and albumin extravasation, and protected against apoptosis and retinal dysfunction. Regarding the involved mechanisms, GLP-1 exerted an anti-inflammatory action by decreasing NF-κB, inflammosome, and pro-inflammatory factors. In addition, it also decreased VEGF expression. Furthermore, GLP-1 promoted cell survival by increasing the anti-apoptotic protein Bcl-xl and the signaling pathway Akt/GSK3b/β-catenin. Finally, Ki67 results revealed that GLP-1 treatment could induce neurogenesis. In conclusion, the topical administration of GLP-1 reverts the impairment of the neurovascular unit by modulating essential pathways involved in the development of diabetic retinopathy (DR). These beneficial effects on the neurovascular unit could pave the way for clinical trials addressed to confirm the effectiveness of GLP-1 in early stages of DR.

Verified
Journal Article
Open access
PDF file
HAHugo Ramos Abellan
Hugo Ramos Abellan
CHCristina Hernandez
Cristina Hernandez
Rafael SimóRafael Simó
Rafael Simó
OSOlga Simo-Servat
Olga Simo-Servat
The etiology of diabetic retinopathy (DR) is complex, multifactorial and compromises all the elements of the retinal neurovascular unit (NVU). This diabetic complication has a chronic low-grade inflammatory component involving multiple inflammatory mediators and adhesion molecules. The diabetic milieu promotes reactive gliosis, pro-inflammatory cytokine production and leukocyte recruitment, which contribute to the disruption of the blood retinal barrier. The understanding and the continuous research of the mechanisms behind the strong inflammatory component of the disease allows the design of new therapeutic strategies to address this unmet medical need. In this context, the aim of this review article is to recapitulate the latest research on the role of inflammation in DR and to discuss the efficacy of currently administered anti-inflammatory treatments and those still under development.